Newsfeeds - Spark Newswire

1 minute read

Cyclo Therapeutics Monday Reported Q2 EPS $(0.56) Beats $(0.76) Estimate, Sales $238.59K Miss $358.00K Estimate

Today, 8:17 AM

Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.76) by 26.32 percent. The company reported quarterly sales of $238.59 thousand which

CYTH

1 minute read

Cyclo Therapeutics’ Trappsol Shows Early Safety, Efficacy In Genetic Disorder

By Vandana Singh

Today, 8:17 AM

Cyclo Therapeutics Inc (NASDAQ:CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1…

CYTH

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 8:17 AM

ADIL

1 minute read

Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo

By Vandana Singh

Today, 8:17 AM

Cyclo Therapeutics Inc (NASDAQ:CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1).…

CYTH

1 minute read

General

Cyclo Therapeutics Highlights Launch Of New Website

By Bill Haddad

Today, 8:17 AM

- Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases - Pivotal Phase 3 study of Trappsol® Cyclo™ for

CYTH